Read our Recent Headlines


Nov 13, 2019 by Jason Chew

Taking a BET on CNST

Constellation Pharmaceuticals is focused on the development of cancer therapeutics by targeting the epigenetic pathway. It has EZH2 and BET inhibitors in mid-stage clinical studies. Excitement in the stock is.

Share 0 Comments Read more
Nov 13, 2019 by Dave Sobek

November 13 Biotech Update

All three SMIDs this week had positive news although only AMRN really took off on it. Of course, AMRN had the smallest positive move into the week and probably had.

Nov 12, 2019 by Dave Sobek

November 12th Biotech Update

I know the actual AdCom is in a couple of days but the briefing docs release today gave us the final move for this weekly trifecta. This could also be.

Nov 11, 2019 by Dave Sobek

November 11 Biotech Update

This is not necessarily a big week for the sector (the trend still seems in intact) but certainly some big SMID catalyst for stocks that I follow. In fact, there.

Nov 06, 2019 by Dave Sobek

November 6 Biotech Update

We remain in what seems like the trend. Day three of the pullbacks tends to be when we restart the move higher but yesterday ended marginally green instead of red.

Nov 05, 2019 by Dave Sobek

November 5th Biotech Update

Let us see if the trend is our friend. We hit what should be some resistance and have stalled. Previously, this led to a day or two of a shallow.

Nov 04, 2019 by Dave Sobek

November 4 Biotech Update

Of course we get some meaningful news when I am unable to write but at least it was good news. And of course the sector does well when I am.

More From All Reports

Introduction


[videojs width="640" preload="auto" ogg="https://s3.amazonaws.com/chimeraresearchgroup.com/video/640ogg.ogg" webm="https://s3.amazonaws.com/chimeraresearchgroup.com/video/640webm.webm" mp4="https://s3.amazonaws.com/chimeraresearchgroup.com/video/640mp4.mp4"]

Overview

Chimera Research Group provides completely independent and actionable investment and trading ideas backed by comprehensive fundamental research and analysis for listed companies in the biotech and pharmaceutical sectors. Our coverage focuses on early stage companies with impending FDA decisions or clinical trial results but also includes mid-to-large cap bio-pharma companies where there exists specific catalysts. Our Trade Ideas are designed to maximize the risk reward profile. Our Research Reports outline the top up-and-coming catalysts that represent the best opportunities for traders and investors.


The biopharmaceutical sector offers significant opportunities to generate big returns yet can be risky and difficult to navigate. Subscribe to Chimera Research Group and proceed with confidence.

Get Started!


      Join      

 Learn More